Brief: Sab Biotherapeutics Says Cash And Cash Equivalents Were $16.6 Mln As Of June 30

SAB Biotherapeutics

10/08/2022 13:28

Aug 10 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE
$16.6
MILLION AS OF JUNE 30, 2022
    * SAB BIOTHERAPEUTICS INC - QTRLY  LOSS PER SHARE $0.11)
    * SAB BIOTHERAPEUTICS - SEES CASH, EQUIVALENTS, AS OF JUNE
30,
2022, TO BE SUFFICIENT TO FUND CAPEX REQUIREMENTS FOR 12 MONTHS
AFTER QTRLY 10-Q REPORT

Source text for Eikon:  ID:nGNXQvScD 
Further company coverage:  SABS.O 

 ((reuters.briefs@thomsonreuters.com;))